Thrombolysis in Myocardial Infarction (TIMI) Trial--phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase

Division of Heart and Vascular Diseases, National Heart, Lung, and Blood Institute, Bethesda, Maryland.

Two hundred ninety patients with acute myocardial infarction were treated according to random assignment with an intravenous infusion of either 80 mg of recombinant tissue plasminogen activator (rt-PA) over 3 h or 1.5 million units of streptokinase over 1 h. Patients received an intravenous bolus of heparin (5,000 U [USP]) before pretreatment coronary angiography and a continuous infusion (1,000 U/h) starting 3 h later. The frequency of major and minor hemorrhagic events (33% rt-PA, 31% streptokinase) and associated transfusions (22% rt-PA, 20% streptokinase) were comparable in both groups. More than 70% of bleeding episodes in each group occurred at catheterization or vascular puncture sites. Precipitable fibrinogen levels, measured in plasma samples collected in the presence of a protease inhibitor (aprotinin), declined in rt-PA and streptokinase groups by averages of 26 and 57% at 3 h and by 33 and 58% at 5 h, respectively (rt-PA versus streptokinase, p less than 0.001). At 5 h the plasma plasminogen declined by 57% (rt-PA) and 82% (streptokinase) (p less than 0.001); plasma fibrin(ogen) degradation products were higher in streptokinase-treated patients (244 +/- 12 micrograms/ml, mean +/- SE) than in rt-PA-treated patients (97 +/- 9 micrograms/ml, p less than 0.001). At 27 h, plasma fibrinogen and plasminogen levels were lower and fibrin(ogen) degradation products higher than pretreatment levels in both groups. The frequency of hemorrhagic events was higher in patients with greater changes in plasma factors at 5 h; within treatment groups the levels of fibrin(ogen) degradation products correlated with bleeding complications (p less than 0.005). Thus, in the doses administered, rt-PA induces systemic fibrinogenolysis that is substantially less intense than that induced by streptokinase. The high frequency of bleeding encountered is related to the protocol used, including vigorous anticoagulation, arterial punctures and thrombolytic therapy. These findings emphasize the need for avoidance of invasive procedures and for meticulous care in the selection and management of patients subjected to thrombolytic therapy.

This article has been cited by other articles:

				E. Stabile, W. Nammas, L. Salemme, G. Sorropago, A. Cioppa, T. Tesorio, V. Ambrosini, E. Campopiano, G. Popusoi, G. Biondi Zoccai, et al. The CIAO (Coronary Interventions Antiplatelet-based Only) Study: A Randomized Study Comparing Standard Anticoagulation Regimen to Absence of Anticoagulation for Elective Percutaneous Coronary Intervention J. Am. Coll. Cardiol., October 14, 2008; 52(16): 1293 - 1298. [Abstract] [Full Text] [PDF]

				G. Patti, A. Nusca, F. Mangiacapra, L. Gatto, A. D'Ambrosio, and G. Di Sciascio Point-of-Care Measurement of Clopidogrel Responsiveness Predicts Clinical Outcome in Patients Undergoing Percutaneous Coronary Intervention: Results of the ARMYDA-PRO (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity Predicts Outcome) Study J. Am. Coll. Cardiol., September 30, 2008; 52(14): 1128 - 1133. [Abstract] [Full Text] [PDF]

				P. P. Dobesh, K. W. Phillips, and S. T. Haines Optimizing antithrombotic therapy in patients with non-ST-segment elevation acute coronary syndrome Am. J. Health Syst. Pharm., August 1, 2008; 65(15_Supplement_7): S22 - S28. [Abstract] [Full Text] [PDF]

				J. C Coons and S. Battistone 2007 Guideline Update for Unstable Angina/Non-ST-Segment Elevation Myocardial Infarction: Focus on Antiplatelet and Anticoagulant Therapies Ann. Pharmacother., July 1, 2008; 42(7): 989 - 1001. [Abstract] [Full Text] [PDF]

				P. Widimsky, Z. Motovska, S. Simek, P. Kala, R. Pudil, F. Holm, R. Petr, D. Bilkova, H. Skalicka, P. Kuchynka, et al. Clopidogrel pre-treatment in stable angina: for all patients >6 h before elective coronary angiography or only for angiographically selected patients a few minutes before PCI? A randomized multicentre trial PRAGUE-8 Eur. Heart J., June 2, 2008; 29(12): 1495 - 1503. [Abstract] [Full Text] [PDF]

				L. Bonello, L. Camoin-Jau, S. Arques, C. Boyer, D. Panagides, O. Wittenberg, M.-C. Simeoni, P. Barragan, F. Dignat-George, and F. Paganelli Adjusted Clopidogrel Loading Doses According to Vasodilator-Stimulated Phosphoprotein Phosphorylation Index Decrease Rate of Major Adverse Cardiovascular Events in Patients With Clopidogrel Resistance: A Multicenter Randomized Prospective Study J. Am. Coll. Cardiol., April 8, 2008; 51(14): 1404 - 1411. [Abstract] [Full Text] [PDF]

				M. Cohen, D. L. Bhatt, J. H. Alexander, G. Montalescot, C. Bode, T. Henry, J.-F. Tamby, J. Saaiman, S. Simek, J. De Swart, et al. Randomized, Double-Blind, Dose-Ranging Study of Otamixaban, a Novel, Parenteral, Short-Acting Direct Factor Xa Inhibitor, in Percutaneous Coronary Intervention: The SEPIA-PCI Trial Circulation, May 22, 2007; 115(20): 2642 - 2651. [Abstract] [Full Text] [PDF]

				J. Saw, D. L. Bhatt, D. J. Moliterno, S. J. Brener, S. R. Steinhubl, A. M. Lincoff, J. E. Tcheng, R. A. Harrington, M. Simoons, T. Hu, et al. The Influence of Peripheral Arterial Disease on Outcomes: A Pooled Analysis of Mortality in Eight Large Randomized Percutaneous Coronary Intervention Trials J. Am. Coll. Cardiol., October 17, 2006; 48(8): 1567 - 1572. [Abstract] [Full Text] [PDF]

				T. Cuisset, C. Frere, J. Quilici, P.-E. Morange, L. Nait-Saidi, J. Carvajal, A. Lehmann, M. Lambert, J.-L. Bonnet, and M.-C. Alessi Benefit of a 600-mg Loading Dose of Clopidogrel on Platelet Reactivity and Clinical Outcomes in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome Undergoing Coronary Stenting J. Am. Coll. Cardiol., October 3, 2006; 48(7): 1339 - 1345. [Abstract] [Full Text] [PDF]

				A Oudot, P G Steg, N Danchin, G Dentan, M Zeller, P Sicard, P Buffet, Y Laurent, L Janin-Manificat, I L'Huillier, et al. Impact of chronic oral anticoagulation on management and outcomes of patients with acute myocardial infarction: data from the RICO survey Heart, August 1, 2006; 92(8): 1077 - 1083. [Abstract] [Full Text] [PDF]

				D P Chew, D L Bhatt, A M Lincoff, K Wolski, and E J Topol Clinical end point definitions after percutaneous coronary intervention and their relationship to late mortality: an assessment by attributable risk Heart, July 1, 2006; 92(7): 945 - 950. [Abstract] [Full Text] [PDF]

				P. Trouillas and R. von Kummer Classification and Pathogenesis of Cerebral Hemorrhages After Thrombolysis in Ischemic Stroke Stroke, February 1, 2006; 37(2): 556 - 561. [Abstract] [Full Text] [PDF]

				J. Dorffler-Melly, F. Mahler, D.-D. Do, J. Triller, and I. Baumgartner Adjunctive Abciximab Improves Patency and Functional Outcome in Endovascular Treatment of Femoropopliteal Occlusions: Initial Experience Radiology, December 1, 2005; 237(3): 1103 - 1109. [Abstract] [Full Text] [PDF]

				J. C Coons, A. L Seybert, M. I Saul, L. Kirisci, and S. L Kane-Gill Outcomes and Costs of Abciximab Versus Eptifibatide for Percutaneous Coronary Intervention Ann. Pharmacother., October 1, 2005; 39(10): 1621 - 1626. [Abstract] [Full Text] [PDF]

				M. Valgimigli, G. Percoco, P. Malagutti, G. Campo, F. Ferrari, D. Barbieri, G. Cicchitelli, E. P. McFadden, F. Merlini, L. Ansani, et al. Tirofiban and Sirolimus-Eluting Stent vs Abciximab and Bare-Metal Stent for Acute Myocardial Infarction: A Randomized Trial JAMA, May 4, 2005; 293(17): 2109 - 2117. [Abstract] [Full Text] [PDF]

				G. Patti, G. Colonna, V. Pasceri, L. L. Pepe, A. Montinaro, and G. Di Sciascio Randomized Trial of High Loading Dose of Clopidogrel for Reduction of Periprocedural Myocardial Infarction in Patients Undergoing Coronary Intervention: Results From the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) Study Circulation, April 26, 2005; 111(16): 2099 - 2106. [Abstract] [Full Text] [PDF]

				G. De Luca, H. Suryapranata, G. W. Stone, D. Antoniucci, J. E. Tcheng, F.-J. Neumann, F. Van de Werf, E. M. Antman, and E. J. Topol Abciximab as Adjunctive Therapy to Reperfusion in Acute ST-Segment Elevation Myocardial Infarction: A Meta-analysis of Randomized Trials JAMA, April 13, 2005; 293(14): 1759 - 1765. [Abstract] [Full Text] [PDF]

				Abciximab Emergent Stroke Treatment Trial Investi Emergency Administration of Abciximab for Treatment of Patients With Acute Ischemic Stroke: Results of a Randomized Phase 2 Trial Stroke, April 1, 2005; 36(4): 880 - 890. [Abstract] [Full Text] [PDF]

				A. Bruno, P. Trouillas, L. Derex, F. Philippeau, N. Nighoghossian, J. Honnorat, M. Hanss, P. French, P. Adeleine, and M. Dechavanne Predicting rtPA Associated ICH in Acute Stroke * Response: Stroke, December 1, 2004; 35(12): 2762 - 2763. [Full Text] [PDF]

				S. D Brouse and V. G Wiesehan Evaluation of Bleeding Complications Associated with Glycoprotein IIb/IIIa Inhibitors Ann. Pharmacother., November 1, 2004; 38(11): 1783 - 1788. [Abstract] [Full Text] [PDF]

				M. A. Smythe, W. E. Dager, and N. M. Patel Managing Complications of Anticoagulant Therapy Journal of Pharmacy Practice, October 1, 2004; 17(5): 327 - 346. [Abstract] [PDF]

				M. Valgimigli, G. Percoco, D. Barbieri, F. Ferrari, G. Guardigli, G. Parrinello, O. Soukhomovskaia, and R. Ferrari The additive value of tirofiban administered with the high-dose bolus in the prevention of ischemic complications during high-risk coronary angioplasty: The advance trial J. Am. Coll. Cardiol., July 7, 2004; 44(1): 14 - 19. [Abstract] [Full Text] [PDF]

				P. Trouillas, L. Derex, F. Philippeau, N. Nighoghossian, J. Honnorat, M. Hanss, P. Ffrench, P. Adeleine, and M. Dechavanne Early Fibrinogen Degradation Coagulopathy Is Predictive of Parenchymal Hematomas in Cerebral rt-PA Thrombolysis: A Study of 157 Cases Stroke, June 1, 2004; 35(6): 1323 - 1328. [Abstract] [Full Text] [PDF]

				M. T Dirksen, G. Laarman, A. W.J van 't Hof, G. Guagliumi, W. A.L Tonino, L. Tavazzi, D. J.G.M Duncker, M. L Simoons, and on behalf of the PARI-MI Investigators The effect of ITF-1697 on reperfusion in patients undergoing primary angioplasty: Safety and efficacy of a novel tetrapeptide, ITF-1697 Eur. Heart J., March 1, 2004; 25(5): 392 - 400. [Abstract] [Full Text] [PDF]

				M. Moscucci, K.A.A. Fox, C. P. Cannon, W. Klein, J. Lopez-Sendon, G. Montalescot, K. White, R.J. Goldberg, and for the GRACE Investigators Predictors of major bleeding in acute coronary syndromes: the Global Registry of Acute Coronary Events (GRACE) Eur. Heart J., October 2, 2003; 24(20): 1815 - 1823. [Abstract] [Full Text] [PDF]

				A. W. Chan, D. J. Moliterno, P. B. Berger, G. W. Stone, P. M. DiBattiste, S. L. Yakubov, S. K. Sapp, K. Wolski, D. L. Bhatt, E. J. Topol, et al. Triple antiplatelet therapy during percutaneous coronary intervention is associated withimproved outcomes including one-year survival: Results from the do tirofiban and reoprogive similar efficacy outcome trial (TARGET) J. Am. Coll. Cardiol., October 1, 2003; 42(7): 1188 - 1195. [Abstract] [Full Text] [PDF]

				S. C. Stamou, E. I. Kapetanakis, R. Lowery, K. A. Jablonski, T. L. Frankel, and P. J. Corso Allogeneic blood transfusion requirements after minimally invasive versus conventional aortic valve replacement: a risk-Adjusted analysis Ann. Thorac. Surg., October 1, 2003; 76(4): 1101 - 1106. [Abstract] [Full Text] [PDF]

				P. P Dobesh, S. L Lanfear, J. R Abu-Shanab, J. E Lakamp, S. Gowda, and M. Y Haikal Outcomes with Changes in Prescribing of Glycoprotein IIb/IIIa Inhibitors in PCI Ann. Pharmacother., October 1, 2003; 37(10): 1375 - 1380. [Abstract] [Full Text] [PDF]

				D. J. Moliterno, J. B. Hermiller, D. J. Kereiakes, E. Yow, R. J. Applegate, G. A. Braden, E. J. Dippel, M. I. Furman, C. L. Grines, N. S. Kleiman, et al. A novel point-of-care enoxaparin monitor for use during percutaneous coronary intervention: Results of the Evaluating Enoxaparin Clotting Times (ELECT) Study J. Am. Coll. Cardiol., September 17, 2003; 42(6): 1132 - 1139. [Abstract] [Full Text] [PDF]

				V. Rukshin, R. Santos, M. Gheorghiu, P. K. Shah, S. Kar, S. Padmanabhan, B. Azarbal, V. T. Tsang, R. Makkar, B. Samuels, et al. A Prospective, Nonrandomized, Open-Labeled Pilot Study Investigating the Use of Magnesium in Patients Undergoing Nonacute Percutaneous Coronary Intervention with Stent Implantation Journal of Cardiovascular Pharmacology and Therapeutics, September 1, 2003; 8(3): 193 - 200. [Abstract] [PDF]

				H. M. Sadeghi, C. L. Grines, H. R. Chandra, S. R. Dixon, J. A. Boura, S. Dukkipati, K. J. Harjai, and W. W. O'Neill Percutaneous coronary interventions in octogenarians: glycoprotein IIb/IIIa receptor inhibitors' safety profile J. Am. Coll. Cardiol., August 6, 2003; 42(3): 428 - 432. [Abstract] [Full Text] [PDF]

				M. A Crouch, J. M Nappi, and K. I Cheang Glycoprotein IIb/IIIa Receptor Inhibitors in Percutaneous Coronary Intervention and Acute Coronary Syndrome Ann. Pharmacother., June 1, 2003; 37(6): 860 - 875. [Abstract] [Full Text] [PDF]

				D. Stewart, M. Kong, V. Novokhatny, G. Jesmok, and V. J. Marder Distinct dose-dependent effects of plasmin and TPA on coagulation and hemorrhage Blood, April 15, 2003; 101(8): 3002 - 3007. [Abstract] [Full Text] [PDF]

				S. Yusuf, S. R. Mehta, F. Zhao, B. J. Gersh, P. J. Commerford, M. Blumenthal, A. Budaj, T. Wittlinger, K. A.A. Fox, and on Behalf of the CURE (Clopidogrel in Unstable ang Early and Late Effects of Clopidogrel in Patients With Acute Coronary Syndromes Circulation, February 25, 2003; 107(7): 966 - 972. [Abstract] [Full Text] [PDF]

				A. M. Lincoff, J. A. Bittl, R. A. Harrington, F. Feit, N. S. Kleiman, J. D. Jackman, I. J. Sarembock, D. J. Cohen, D. Spriggs, R. Ebrahimi, et al. Bivalirudin and Provisional Glycoprotein IIb/IIIa Blockade Compared With Heparin and Planned Glycoprotein IIb/IIIa Blockade During Percutaneous Coronary Intervention: REPLACE-2 Randomized Trial JAMA, February 19, 2003; 289(7): 853 - 863. [Abstract] [Full Text] [PDF]

				T. R. Tolleson, J. C. O'Shea, J. A. Bittl, W. B. Hillegass, K. A. Williams, G. Levine, R. A. Harrington, and J. E. Tcheng Relationship between heparin anticoagulation and clinical outcomes in coronary stent intervention: observations from the ESPRIT trial J. Am. Coll. Cardiol., February 5, 2003; 41(3): 386 - 393. [Abstract] [Full Text] [PDF]

				J. D. Marmur, S. X. Anand, R. S. Bagga, J. Fareed, C.-M. Pan, S. K. Sharma, and M. F. Richard The activated clotting time can be used to monitor the low molecular weight heparin dalteparin after intravenous administration J. Am. Coll. Cardiol., February 5, 2003; 41(3): 394 - 402. [Abstract] [Full Text] [PDF]

				D. L. Bhatt, B. I. Lee, P. J. Casterella, M. Pulsipher, M. Rogers, M. Cohen, V. E. Corrigan, T. J. Ryan Jr, J. A. Breall, J. W. Moses, et al. Safety of concomitant therapy with eptifibatide and enoxaparin in patients undergoing percutaneous coronary intervention: Results of the coronary revascularization using integrilin and single bolus enoxaparin study J. Am. Coll. Cardiol., January 1, 2003; 41(1): 20 - 25. [Abstract] [Full Text] [PDF]

				M. Roffi, D. Mukherjee, D. P. Chew, D. L. Bhatt, L. Cho, M. A. Robbins, K. M. Ziada, D. M. Brennan, S. G. Ellis, and E. J. Topol Lack of Benefit From Intravenous Platelet Glycoprotein IIb/IIIa Receptor Inhibition as Adjunctive Treatment for Percutaneous Interventions of Aortocoronary Bypass Grafts: A Pooled Analysis of Five Randomized Clinical Trials Circulation, December 10, 2002; 106(24): 3063 - 3067. [Abstract] [Full Text] [PDF]

				S. James, P. Armstrong, R. Califf, S. Husted, F. Kontny, M. Niemminen, M. Pfisterer, M.L. Simoons, and L. Wallentin Safety and efficacy of abciximab combined with dalteparin in treatment of acute coronary syndromes Eur. Heart J., October 1, 2002; 23(19): 1538 - 1545. [Abstract] [Full Text] [PDF]

				L. S. Fernandes, J. E. Tcheng, J. C. O'Shea, B. Weiner, T. J. Lorenz, C. Pacchiana, L. G. Berdan, K. J. Maresh, D. Joseph, M. Madan, et al. Is glycoprotein IIb/IIIa antagonism as effective in women as in men following percutaneous coronary intervention?: Lessons from the ESPRIT study J. Am. Coll. Cardiol., September 18, 2002; 40(6): 1085 - 1091. [Abstract] [Full Text] [PDF]

				M. A. Brouwer, P. J.P.C. van den Bergh, W. R.M. Aengevaeren, G. Veen, H. E. Luijten, D. P. Hertzberger, A. J. van Boven, R. P.J.W. Vromans, G. J.H. Uijen, and F. W.A. Verheugt Aspirin Plus Coumarin Versus Aspirin Alone in the Prevention of Reocclusion After Fibrinolysis for Acute Myocardial Infarction: Results of the Antithrombotics in the Prevention of Reocclusion In Coronary Thrombolysis (APRICOT)-2 Trial Circulation, August 6, 2002; 106(6): 659 - 665. [Abstract] [Full Text] [PDF]

				G. W. Stone, D. J. Moliterno, M. Bertrand, F.-J. Neumann, H. C. Herrmann, E. R. Powers, C. L. Grines, J. W. Moses, D. J. Cohen, E. A. Cohen, et al. Impact of Clinical Syndrome Acuity on the Differential Response to 2 Glycoprotein IIb/IIIa Inhibitors in Patients Undergoing Coronary Stenting: The TARGET Trial* Circulation, May 21, 2002; 105(20): 2347 - 2354. [Abstract] [Full Text] [PDF]

				J. de Jonge, T. H. N. Groenland, H. J. Metselaar, J. N. M. IJzermans, H. H. D. M. van Vliet, L. Visser, and H. W. Tilanus Fibrinolysis During Liver Transplantation Is Enhanced by Using Solvent/Detergent Virus-Inactivated Plasma (ESDEP(R)) Anesth. Analg., May 1, 2002; 94(5): 1127 - 1131. [Abstract] [Full Text] [PDF]

				P.K Coussement, J.-P Bassand, C Convens, M Vrolix, J Boland, G Grollier, R Michels, A Vahanian, M Vanderheyden, H.-J Rupprecht, et al. A synthetic factor-Xa inhibitor (ORG31540/SR9017A) as an adjunct to fibrinolysis in acute myocardial infarction. The PENTALYSE study Eur. Heart J., September 2, 2001; 22(18): 1716 - 1724. [Abstract] [PDF]

				The Clopidogrel in Unstable Angina to Prevent Recu Effects of Clopidogrel in Addition to Aspirin in Patients with Acute Coronary Syndromes without ST-Segment Elevation N. Engl. J. Med., August 16, 2001; 345(7): 494 - 502. [Abstract] [Full Text] [PDF]

				F Ferrari, F Vagnarelli, G Gargano, M F Roversi, O Biagioni, A Ranzi, and G B Cavazzuti Early intracardiac thrombosis in preterm infants and thrombolysis with recombinant tissue type plasminogen activator Arch. Dis. Child. Fetal Neonatal Ed., July 1, 2001; 85(1): F66 - 69. [Abstract] [Full Text] [PDF]

				E. J. Topol, D. J. Moliterno, H. C. Herrmann, E. R. Powers, C. L. Grines, D. J. Cohen, E. A. Cohen, M. Bertrand, F.-J. Neumann, G. W. Stone, et al. Comparison of Two Platelet Glycoprotein IIb/IIIa Inhibitors, Tirofiban and Abciximab, for the Prevention of Ischemic Events with Percutaneous Coronary Revascularization N. Engl. J. Med., June 21, 2001; 344(25): 1888 - 1894. [Abstract] [Full Text] [PDF]

				G. Montalescot, P. Barragan, O. Wittenberg, P. Ecollan, S. Elhadad, P. Villain, J.-M. Boulenc, M.-C. Morice, L. Maillard, M. Pansieri, et al. Platelet Glycoprotein IIb/IIIa Inhibition with Coronary Stenting for Acute Myocardial Infarction N. Engl. J. Med., June 21, 2001; 344(25): 1895 - 1903. [Abstract] [Full Text] [PDF]

				K M Akkerhuis, M J B M van den Brand, C van der Zwaan, H O J Peels, H Suryapranata, L R van der Wieken, J Stibbe, J Hoffmann, T Baardman, J W Deckers, et al. Pharmacodynamics and safety of lefradafiban, an oral platelet glycoprotein IIb/IIIa receptor antagonist, in patients with stable coronary artery disease undergoing elective angioplasty Heart, April 1, 2001; 85(4): 444 - 450. [Abstract] [Full Text]

				S. R. Steinhubl, S. G. Ellis, K. Wolski, A. M. Lincoff, and E. J. Topol Ticlopidine Pretreatment Before Coronary Stenting Is Associated With Sustained Decrease in Adverse Cardiac Events : Data From the Evaluation of Platelet IIb/IIIa Inhibitor for Stenting (EPISTENT) Trial Circulation, March 13, 2001; 103(10): 1403 - 1409. [Abstract] [Full Text] [PDF]

				E. I. Lev, J. I. Osende, M. F. Richard, J. A. Robbins, J. A. Delfin, O. Rodriguez, S. K. Sharma, T. Jayasundera, J. J. Badimon, and J. D. Marmur Administration of abciximab to patients receiving tirofiban or eptifibatide: effect on platelet function J. Am. Coll. Cardiol., March 1, 2001; 37(3): 847 - 855. [Abstract] [Full Text] [PDF]

				J. J. Popma, E. M. Ohman, J. Weitz, A. M. Lincoff, R. A. Harrington, and P. Berger Antithrombotic Therapy in Patients Undergoing Percutaneous Coronary Intervention Chest, January 1, 2001; 119(1_suppl): 321S - 336S. [Full Text] [PDF]

				A. M. Lincoff, D. B. Mark, J. E. Tcheng, R. M. Califf, M. V. Bala, K. M. Anderson, L. Davidson-Ray, J. D. Knight, C. F. Cabot, and E. J. Topol Economic Assessment of Platelet Glycoprotein IIb/IIIa Receptor Blockade With Abciximab and Low-Dose Heparin During Percutaneous Coronary Revascularization : Results From the EPILOG Randomized Trial Circulation, December 12, 2000; 102(24): 2923 - 2929. [Abstract] [Full Text] [PDF]

				K. M. Akkerhuis, K.-L. Neuhaus, R. G. Wilcox, A. Vahanian, J.-L. Boland, J. Hoffmann, T. Baardman, G. Nehmiz, U. Roth, A. P. J. Klootwijk, et al. Safety and preliminary efficacy of one month glycoprotein IIb/IIIa inhibition with lefradafiban in patients with acute coronary syndromes without ST-elevation A phase II study Eur. Heart J., December 2, 2000; 21(24): 2042 - 2055. [Abstract] [PDF]

				A. M. Lincoff, R. A. Harrington, R. M. Califf, J. S. Hochman, A. D. Guerci, E. M. Ohman, C. J. Pepine, S. L. Kopecky, N. S. Kleiman, C. M. Pacchiana, et al. Management of Patients With Acute Coronary Syndromes in the United States by Platelet Glycoprotein IIb/IIIa Inhibition : Insights From the Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) Trial Circulation, September 5, 2000; 102(10): 1093 - 1100. [Abstract] [Full Text] [PDF]

				M. T. Roe, R. A. Harrington, D. M. Prosper, K. S. Pieper, D. L. Bhatt, A. M. Lincoff, M. L. Simoons, M. Akkerhuis, E. M. Ohman, M. M. Kitt, et al. Clinical and Therapeutic Profile of Patients Presenting With Acute Coronary Syndromes Who Do Not Have Significant Coronary Artery Disease Circulation, September 5, 2000; 102(10): 1101 - 1106. [Abstract] [Full Text] [PDF]